Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Source: SeekingAlpha
2026-01-05 13:19:56 ET
EQUITY RESEARCH: PHARMACEUTICALS
Company: Tenax Therapeutics ( TENX )
Investment Rating: BUY
Risk Profile: Speculative/ High Risk
First Price Target (12-months): $25
Current Price = $11.05
Upside: 127%
TENX price chart (Seeking Alpha)
Executive Summary
Read the full article on Seeking Alpha
For further details see:
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Tenax Therapeutics Inc.
NASDAQ: TENX
TENX Trading
-6.06% G/L:
$11.32 Last:
145,064 Volume:
$11.72 Open:
TENX Latest News
February 04, 2026 07:00:00 am
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
December 17, 2025 09:16:49 am
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
November 12, 2025 04:05:00 pm
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
TENX Stock Data
$80,229,939
6,047,527
14.41%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Chapel Hill
